Zacks Investment Research upgraded shares of LIGAND PHARMA-B (LGND) from UNDERPERFORM to NEUTRAL on March 06, 2013, with a target price of $22.50.
Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on LIGAND PHARMA-B (LGND),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment